The FDA has approved glucarpidase (Voraxaze, BTG International) for treating patients with toxic levels of methotrexate—a type of chemotherapy—in the blood due to kidney failure. The drug breaks down methotrexate to a form that the body is able to eliminate.
Source: FDA newsroom.
